Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction

Clinical Endocrinology

Volumn 80, Issue 6, 2014, Pages 918-924

  Hindricks, Janka ^a,b   Ebert, Thomas ^a,b   Bachmann, Anette ^a   Kralisch, Susan ^a,b   Lössner, Ulrike ^a,b   Kratzsch, Jürgen ^a   Stolzenburg, Jens Uwe ^a   Dietel, Anja ^a   Beige, Joachim ^c   Anders, Matthias ^d   Bast, Ingolf ^d   Blüher, Matthias ^a   Stumvoll, Michael ^a   Fasshauer, Mathias ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c Klinikum St Georg   (Germany)

^d Outpatient Nephrology Care Units   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL COMPOSITION; CHRONIC KIDNEY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNINEPHRECTOMY; AGED; ANTHROPOMETRY; BLOOD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; INSULIN RESISTANCE; KIDNEY FAILURE; NEPHRECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTHROPOMETRY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; NEPHRECTOMY; RENAL INSUFFICIENCY; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84899587333     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12380     Document Type: Article

References (35)

1. Hajer, G.R., van Haeften, T.W., &, Visseren, F.L.J,. (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. European Heart Journal, 29, 2959-2971.
2. Kharitonenkov, A., Shiyanova, T.L., Koester, A., et al,. (2005) FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation, 115, 1627-1635.
3. Sarruf, D.A., Thaler, J.P., Morton, G.J., et al,. (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes, 59, 1817-1824.
4. Lin, Z., Wu, Z., Yin, X., et al,. (2010) Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE, 5, e15534.
5. Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., et al,. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care, 32, 1542-1546.
6. Stein, S., Bachmann, A., Lössner, U., et al,. (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care, 32, 126-128.
7. Han, S.H., Choi, S.H., Cho, B.J., et al,. (2010) Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism, 59, 1656-1662.
8. Lin, Z., Zhou, Z., Liu, Y., et al,. (2011) Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE, 6, e18398.
9. Richter, J., Focke, D., Ebert, T., et al,. (2013) Serum levels of the adipokine progranulin depend on renal function. Diabetes Care, 36, 410-414.
10. Levey, A.S., Bosch, J.P., Lewis, J.B., et al,. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of Internal Medicine, 130, 461-470.
11. Levey, A.S., Coresh, J., Balk, E., et al,. (2003) National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine, 139, 137-147.
12. Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al,. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-419.
13. Siebels, M., Theodorakis, J., Schmeller, N., et al,. (2003) Risks and complications in 160 living kidney donors who underwent nephroureterectomy. Nephrology Dialysis Transplantation, 18, 2648-2654.
14. Argiles, A., Mourad, G., Basset, N., et al,. (1987) Acute adaptative changes to unilateral nephrectomy in humans. Kidney International, 32, 714-720.
15. Richter, J., Ebert, T., Stolzenburg, J.-U., et al,. (2013) Response to comment on: Richter et al. Serum levels of the adipokine progranulin depend on renal function. Diabetes Care 2013;36:410-414. Diabetes Care, 36, e84.
16. Levey, A.S., Stevens, L.A., Schmid, C.H., et al,. (2009) A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150, 604-612.
17. Zhang, M.H., Spies, C., Ali, S., et al,. (2009) Adiponectin and inducible ischemia in patients with stable coronary heart disease: data from the Heart and Soul study. Atherosclerosis, 205, 233-238.
18. Li, S., Shin, H., Ding, E.L., et al,. (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 302, 179-188.
19. Almagor, M., Mintz, A., Sibirsky, O., et al,. (2005) Preoperative and postoperative levels of interleukin-6 in patients with acute appendicitis: comparison between open and laparoscopic appendectomy. Surgical Endoscopy and Other Interventional Techniques, 19, 331-333.
20. Yu, H., Xia, F., Lam, K.S.L., et al,. (2011) Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clinical Chemistry, 57, 691-700.
21. Holland, W.L., Adams, A.C., Brozinick, J.T., et al,. (2013) An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metabolism, 17, 790-797.
22. Kharitonenkov, A., Wroblewski, V.J., Koester, A., et al,. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 148, 774-781.
23. Coskun, T., Bina, H.A., Schneider, M.A., et al,. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 149, 6018-6027.
24. Kahn, B.B., &, Flier, J.S., (2000) Obesity and insulin resistance. Journal of Clinical Investigation, 106, 473-481.
25. Fisher, F.M., Chui, P.C., Antonellis, P.J., et al,. (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes, 59, 2781-2789.
26. Zhang, X., Yeung, D.C.Y., Karpisek, M., et al,. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57, 1246-1253.
27. Yusuf, S., Hawken, S., Ôunpuu, S., et al,. (2005) Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. The Lancet, 366, 1640-1649.
28. Ashwell, M., Cole, T.J., &, Dixon, A.K., (1996) Ratio of waist circumference to height is strong predictor of intra-abdominal fat. British Medical Journal, 313, 559-560.
29. Lee, Y., Lim, S., Hong, E.-S., et al,. (2014) Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clinical Endocrinology, 80, 57-64.
30. Li, X., Fan, X., Ren, F., et al,. (2011) Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Research and Clinical Practice, 93, 10-16.
31. Stein, S., Stepan, H., Kratzsch, J., et al,. (2010) Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism, 59, 33-37.
32. Stepan, H., Kley, K., Hindricks, J., et al,. (2013) Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia. Cytokine, 62, 322-326.
33. Do, H.T., Tselykh, T.V., Mäkelä, J., et al,. (2012) Fibroblast growth factor-21 (FGF21) regulates low-density lipoprotein receptor (LDLR) levels in cells via the E3-ubiquitin ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting saposin-like protein (Msap). Journal of Biological Chemistry, 287, 12602-12611.
34. Chen, C., Cheung, B.M.Y., Tso, A.W.K., et al,. (2011) High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care, 34, 2113-2115.
35. Kotulák, T., Drápalová, J., Kopecký, P., et al,. (2011) Increased circulating and epicardial adipose tissue mRNA expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance. Physiological Research/Academia Scientiarum Bohemoslovaca, 60, 757-767.